for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lilly-Vir's COVID-19 antibody combo reduced viral load in study

March 29 (Reuters) - Eli Lilly, Vir Biotech and partner GlaxoSmithKline said on Monday Lilly’s antibody therapy in combination with Vir’s antibody drug candidate reduced viral load in low-risk COVID-19 patients in a mid-stage trial.

The trial is testing Lilly’s bamlanivimab given in combination with Vir/GlaxoSmithKline’s VIR-7831. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up